TechCrunch Startup News Why investors just bet $85M on this Indian company’s generic drug strategy
Aug 12, 2025
A Mumbai startup is shaking up the e-pharmacy market with a fresh approach to affordable healthcare. Their unique strategy centers on consumer education, helping to double their revenue and gain investor confidence. With an impressive $85M funding boost, this company is poised for significant expansion in the generic medicine sector. Discover how they are transforming access to healthcare in India and setting new standards for online pharmacies.
AI Snips
Chapters
Transcript
Episode notes
Generic-First Strategy Scaled Valuation
- TrueMeds focused on affordability by promoting generics instead of chasing speed or discounts like competitors.
- That strategy attracted investors and led to an $85M raise and a valuation over $400M.
Founders' Origin In A Crowded Market
- TrueMeds entered a crowded e-pharmacy market in 2019 and chose a different path focusing on generics.
- Founders saw nobody in the value chain working to make medicines affordable, so they aimed to bridge that gap.
Niche Focus Drove Fast Revenue Growth
- TrueMeds targets generic medicines and recommends lower-cost alternatives to branded prescriptions.
- The approach drove revenue to 5 billion rupees with 66% year-over-year growth.